Bilayer Therapeutics, Inc.
Monday, June 03, 2024
Metabolic Diseases
Company Presentation Theater 2
Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat several diseases of the colon using an incretin-based mechanism of action and a unique and proprietary colonic delivery technology developed in Bob Langer’s lab at MIT. BL-050, an orally available therapy for metabolic disorders such as obesity and diabetes, acts through increasing native levels of GLP-1, GLP-2, PYY, glucagon, neurotensin, OXM, and CCK. BL-010, also orally available, acts on the receptor TGR5 and has the potential to treat several types of chronic constipation. There are additional product candidates.
Company Website:
http://www.bilayer-therapeutics.com
Lead Product in Development:
BL-050 for metabolic disorder (obesity/diabetes)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Cambridge
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
Thomas A. Collet
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
.jpg)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())